When talking about solid dosage form production, in nine out of ten cases containment immediately becomes an issue.

Why?
The first reason is that APIs are becoming more and more potent. According to an estimation by ISPE (Winter Conference Berlin 2002), by 2010 more than 85 % of all NCE will be classified potent (OEL < 10 µg/m³). The second reason is that health and safety authorities all around the world are putting more focus on the protection of operators dealing with these substances. The third reason is that suppliers of various hardware components have developed a huge variety of containment solutions, making it difficult to decide on the optimal solution, even for experienced people.

A NEW article from Dr. Harald Stahl
Dr Harald Stahl is a Senior Pharmaceutical Technologist with GEA Pharma Systems. He is an executive member of the ISPE Containment Community of Practice (CCOP), and has published more than 20 papers on various aspects of solid dosage form production, of which several have a special focus on containment aspects. Dr Stahl holds a Diploma in Physics and a PhD in Chemical Engineering.

Launch in external player

Buck® and Buck Systems™ technology, allows docking and undocking operations to be carried out in a non controlled environment.